- Conditions
- Crohn's Disease
- Interventions
- Matching Placebo for Upadacitinib, Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 624 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 119
- States / cities
- Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 92 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 5,344
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia, Acute Myeloid Leukemia
- Interventions
- Idarubincin and Amufostine (Ethyol), Idarubincin
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 15
- States / cities
- San Diego, California • Chicago, Illinois • New Albany, Indiana + 12 more
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib, Dexamethasone, Lenalidomide, Cilta-cel, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 743 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2036
- U.S. locations
- 19
- States / cities
- San Francisco, California • New Haven, Connecticut • Miami, Florida + 13 more
- Conditions
- Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
- Interventions
- Durvalumab, Regorafenib
- Biological · Drug
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Milwaukee, Wisconsin
- Conditions
- Pediatric Pulmonary Hypertension
- Interventions
- Mono-Therapy with Sildenafil, Duo-Therapy with Sildenafil + Bosentan
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 3 Months to 18 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • St. Petersburg, Florida • Baltimore, Maryland + 7 more
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin, Pom/dex (Pomalidomide plus low dose Dexamethasone)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Pueblo, Colorado • Detroit, Michigan + 7 more
- Conditions
- Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer, Castrate Resistant Prostate Cancer, Hormone Sensitive Prostate Cancer, Non-metastatic Prostate Cancer
- Interventions
- Darolutamide, Enzalutamide
- Drug
- Lead sponsor
- Alliance Foundation Trials, LLC.
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 8
- States / cities
- San Francisco, California • Chicago, Illinois • Fairway, Kansas + 4 more
- Conditions
- Pain
- Interventions
- morphine sulfate extended release capsules
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 1,570 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 378
- States / cities
- Adamsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 314 more
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Heart Failure，Congestive, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction, Heart Failure; With Decompensation
- Interventions
- CardioMEMS™ HF System
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 125
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 100 more
- Conditions
- Adult Lower Limb Spasticity
- Interventions
- Not listed
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 16
- States / cities
- Downey, California • Washington D.C., District of Columbia • Leawood, Kansas + 13 more
- Conditions
- Chronic Pancreatitis
- Interventions
- Tanezumab, Placebo
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 9
- States / cities
- Naples, Florida • Wellington, Florida • Tupelo, Mississippi + 3 more
- Conditions
- Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
- Interventions
- Fabrazyme (agalsidase beta)
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 9
- States / cities
- Farmington, Connecticut • Coral Springs, Florida • Kansas City, Kansas + 6 more
- Conditions
- Post-ERCP Pancreatitis
- Interventions
- Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement, Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement
- Other
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,950 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Denver, Colorado • Orlando, Florida + 15 more
- Conditions
- Heart Failure, Cardiomyopathies
- Interventions
- EXCOR Pediatric
- Device
- Lead sponsor
- Berlin Heart, Inc
- Industry
- Eligibility
- 1 Day to 16 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 12 more
- Conditions
- Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
- Interventions
- Adavosertib, Paclitaxel, Carboplatin, Gemcitabine, PLD
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 18
- States / cities
- Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 14 more
- Conditions
- Post-Traumatic Stress Disorder
- Interventions
- CAPS/WHODAS, Nonstructured Interview
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 11
- States / cities
- North Little Rock, Arkansas • Palo Alto, California • West Haven, Connecticut + 8 more
- Conditions
- Sickle Cell Disease
- Interventions
- Defibrotide
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Gainesville, Florida • Valhalla, New York + 1 more
- Conditions
- Safety and Effectiveness of the Siello S Lead
- Interventions
- market-released BIOTRONIK pacemaker system including one or two Siello S leads.
- Device
- Lead sponsor
- Biotronik, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,758 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 53
- States / cities
- La Jolla, California • La Mesa, California • New Haven, Connecticut + 50 more
- Conditions
- Weight Loss, Obesity
- Interventions
- lifestyle intervention with meal replacement program
- Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Community-acquired Pneumonia
- Interventions
- Heparin
- Drug
- Lead sponsor
- University of Manitoba
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Jefferson, Louisiana • Portland, Maine + 3 more
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Respiratory Distress Syndrome (RDS), Sepsis, Pneumonia, Hypertension, Pulmonary
- Interventions
- Inhaled nitric oxide, Placebo
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 120 Hours
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Diego, California + 14 more
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Peripheral T-cell Lymphoma, Previously Treated Myelodysplastic Syndromes, Progressive Hairy Cell Leukemia, Initial Treatment, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Splenic Marginal Zone Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Childhood Anaplastic Large Cell Lymphoma, Stage I Childhood Large Cell Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Childhood Anaplastic Large Cell Lymphoma, Stage II Childhood Large Cell Lymphoma, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Childhood Anaplastic Large Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Childhood Anaplastic Large Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Waldenström Macroglobulinemia
- Interventions
- alemtuzumab, fludarabine phosphate, total-body irradiation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, mycophenolate mofetil, cyclosporine
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 74 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Salt Lake City, Utah • Seattle, Washington + 1 more
- Conditions
- PHACE Syndrome
- Interventions
- Not listed
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Pre-term Infants
- Interventions
- study pre-term formula
- Other
- Lead sponsor
- Abbott Nutrition
- Industry
- Eligibility
- Up to 21 Days
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- Mobile, Alabama • South Bend, Indiana • Wichita, Kansas + 4 more